Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $193.32 million. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. It currently has negative earnings. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Analysts expect NTN Buzztime Inc (NYSEMKT:NTN) to report $-0.39 EPS on May, 5.They anticipate $0.11 EPS change or 22.00% from last quarter’s $-0.5 EPS. After having $-0.22 EPS previously, NTN Buzztime Inc’s analysts see 77.27% EPS growth. About 23,597 shares traded. NTN Buzztime Inc (NYSEMKT:NTN) has risen 0.27% since September 14, 2016 and is uptrending. It has underperformed by 10.55% the S&P500.
About 40,563 shares traded. Fate Therapeutics Inc (NASDAQ:FATE) has risen 71.22% since September 14, 2016 and is uptrending. It has outperformed by 60.39% the S&P500.
Polaris Venture Management Co. V L.L.C. holds 7.37% of its portfolio in Fate Therapeutics Inc for 2.47 million shares. Bvf Inc Il owns 3.76 million shares or 1.9% of their US portfolio. Moreover, Kingdon Capital Management L.L.C. has 0.32% invested in the company for 2.62 million shares. The California-based Redmile Group Llc has invested 0.31% in the stock. Bridgeway Capital Management Inc, a Texas-based fund reported 250,000 shares.
Ratings analysis reveals 100% of Fate Therapeutics’s analysts are positive. Out of 6 Wall Street analysts rating Fate Therapeutics, 6 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $4 while the high is $8. The stock’s average target of $6.75 is 49.34% above today’s ($4.52) share price. FATE was included in 6 notes of analysts from October 6, 2015. Raymond James initiated Fate Therapeutics Inc (NASDAQ:FATE) rating on Tuesday, October 6. Raymond James has “Outperform” rating and $8 target. As per Friday, December 4, the company rating was initiated by Wells Fargo. As per Tuesday, April 12, the company rating was initiated by BMO Capital Markets. As per Tuesday, November 8, the company rating was maintained by Wedbush. The stock of Fate Therapeutics Inc (NASDAQ:FATE) earned “Buy” rating by TH Capital on Thursday, September 22. Roth Capital initiated the shares of FATE in report on Thursday, September 22 with “Buy” rating.
Since January 1, 0001, it had 3 insider purchases, and 0 sales for $1.25 million activity.
NTN Buzztime, Inc., formerly Alroy Industries, delivers entertainment and dining technology to bars and restaurants in North America. The company has market cap of $18.48 million. The Firm provides an entertainment and marketing services platform for hospitality venues that offers games, events, and entertainment experiences to their customers. It currently has negative earnings. The Company’s clients offer guests trivia, card, sports and arcade games, nationwide competitions, and self-service dining features, including dynamic menus, touchscreen ordering and secure payment by licensing the Company’s customizable solution.
Investors sentiment decreased to 0 in Q4 2016. Its down 0.83, from 0.83 in 2016Q3. It dropped, as 0 investors sold NTN Buzztime Inc shares while 0 reduced holdings. 0 funds opened positions while 1 raised stakes. 828,842 shares or 204.86% more from 271,880 shares in 2016Q3 were reported. Eagle Asset Inc holds 0.01% in NTN Buzztime Inc (NYSEMKT:NTN) or 90,230 shares. Awm Inv Co Inc holds 0.54% of its portfolio in NTN Buzztime Inc (NYSEMKT:NTN) for 324,191 shares.
